Article

DNA Methylation, Isocitrate Dehydrogenase Mutation, and Survival in Glioma

Department of Pathology and Laboratory Medicine, Brown University, Providence, RI, USA.
CancerSpectrum Knowledge Environment (Impact Factor: 15.16). 07/2011; 103(2):143-53. DOI: 10.1093/jnci/djq497
Source: PubMed

ABSTRACT Although much is known about molecular and chromosomal characteristics that distinguish glioma histological subtypes, DNA methylation patterns of gliomas and their association with other tumor features such as mutation of isocitrate dehydrogenase (IDH) genes have only recently begun to be investigated.
DNA methylation of glioblastomas, astrocytomas, oligodendrogliomas, oligoastrocytomas, ependymomas, and pilocytic astrocytomas (n = 131) from the Brain Tumor Research Center at the University of California San Francisco, as well as nontumor brain tissues (n = 7), was assessed with the Illumina GoldenGate methylation array. Methylation data were subjected to recursively partitioned mixture modeling (RPMM) to derive methylation classes. Differential DNA methylation between tumor and nontumor was also assessed. The association between methylation class and IDH mutation (IDH1 and IDH2) was tested using univariate and multivariable analysis for tumors (n = 95) with available substrate for sequencing. Survival of glioma patients carrying mutant IDH (n = 57) was compared with patients carrying wild-type IDH (n = 38) using a multivariable Cox proportional hazards model and Kaplan-Meier analysis. All statistical tests were two-sided.
We observed a statistically significant association between RPMM methylation class and glioma histological subtype (P < 2.2 × 10(-16)). Compared with nontumor brain tissues, across glioma tumor histological subtypes, the differential methylation ratios of CpG loci were statistically significantly different (permutation P < .0001). Methylation class was strongly associated with IDH mutation in gliomas (P = 3.0 × 10(-16)). Compared with glioma patients whose tumors harbored wild-type IDH, patients whose tumors harbored mutant IDH showed statistically significantly improved survival (hazard ratio of death = 0.27, 95% confidence interval = 0.10 to 0.72).
The homogeneity of methylation classes for gliomas with IDH mutation, despite their histological diversity, suggests that IDH mutation is associated with a distinct DNA methylation phenotype and an altered metabolic profile in glioma.

0 Followers
 · 
130 Views
  • Source
    • "TES is expressed in a wide range of adult human tissues, including brain (Tatarelli et al. 2000), and has been previously shown to inhibit tumorigenicity of human cancer cell lines (Tobias et al. 2001). DNA hypermethylation of the TES promoter is one of the most frequent epigenetic disruptions in primary GBM (;60% of cases) (Mueller et al. 2007; Martinez et al. 2009; Christensen et al. 2011) and is also observed in other human cancers (Qiu et al. 2010; Weeks et al. 2010). We analyzed methylation profiles generated for 67 GBM samples by The Cancer Genome Atlas (TCGA) project. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Epigenetic changes are frequently observed in cancer. However, their role in establishing or sustaining the malignant state has been difficult to determine due to the lack of experimental tools that enable resetting of epigenetic abnormalities. To address this, we applied induced pluripotent stem cell (iPSC) reprogramming techniques to invoke widespread epigenetic resetting of glioblastoma (GBM)-derived neural stem (GNS) cells. GBM iPSCs (GiPSCs) were subsequently redifferentiated to the neural lineage to assess the impact of cancer-specific epigenetic abnormalities on tumorigenicity. GiPSCs and their differentiating derivatives display widespread resetting of common GBM-associated changes, such as DNA hypermethylation of promoter regions of the cell motility regulator TES (testis-derived transcript), the tumor suppressor cyclin-dependent kinase inhibitor 1C (CDKN1C; p57KIP2), and many polycomb-repressive complex 2 (PRC2) target genes (e.g., SFRP2). Surprisingly, despite such global epigenetic reconfiguration, GiPSC-derived neural progenitors remained highly malignant upon xenotransplantation. Only when GiPSCs were directed to nonneural cell types did we observe sustained expression of reactivated tumor suppressors and reduced infiltrative behavior. These data suggest that imposing an epigenome associated with an alternative developmental lineage can suppress malignant behavior. However, in the context of the neural lineage, widespread resetting of GBM-associated epigenetic abnormalities is not sufficient to override the cancer genome.
    Genes & development 03/2013; 27(6):654-69. DOI:10.1101/gad.212662.112 · 12.64 Impact Factor
  • Source
    • "A subset of primary GBMs exhibit the ''CpG island methylator phenotype'' (CIMP) and show concordant hypermethylation of a large number of CpG islands (Toyota and Issa 1999; Toyota et al. 1999; Noushmehr et al. 2010). Interestingly, in gliomas, the CIMP phenotype (termed G-CIMP) has a striking association with IDH1 mutation (Noushmehr et al. 2010; Christensen et al. 2011; Laffaire et al. 2011; Turcan et al. 2012). Similarly, IDH1 and IDH2 mutations robustly associate with specific global DNA hypermethylation phenotypes in AMLs (Figueroa et al. 2010a), enchondromas (Pansuriya et al. 2011), and low-grade gliomas (LGGs) (Turcan et al. 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Monoallelic point mutations of the NADP(+)-dependent isocitrate dehydrogenases IDH1 and IDH2 occur frequently in gliomas, acute myeloid leukemias, and chondromas and display robust association with specific DNA hypermethylation signatures. Here we show that heterozygous expression of the IDH1(R132H) allele is sufficient to induce the genome-wide alterations in DNA methylation characteristic of these tumors. Using a gene targeting approach, we knocked-in a single copy of the most frequently observed IDH1 mutation, R132H, into a human cancer cell line and profiled changes in DNA methylation at over 27,000 CpG dinucleotides relative to wild-type parental cells. We find that IDH1(R132H/WT) mutation induces widespread alterations in DNA methylation, including hypermethylation of 2,010 and hypomethylation of 842 CpG loci. We demonstrate that many of these alterations are consistent with those observed in IDH1-mutant and G-CIMP+ primary gliomas and can segregate IDH wild-type and mutated tumors, as well as those exhibiting the G-CIMP phenotype in unsupervised analysis of two primary glioma cohorts. Further, we show that the direction of IDH1(R132H/WT)-mediated DNA methylation change is largely dependent upon pre-existing DNA methylation levels, resulting in depletion of moderately methylated loci. Additionally, whereas the levels of multiple histone H3 and H4 methylation modifications were globally increased, consistent with broad inhibition of histone demethylation, hypermethylation at H3K9 in particular accompanied locus-specific DNA hypermethylation at several genes downregulated in IDH1(R132H/WT) knock-in cells. These data provide insight on epigenetic alterations induced by IDH1 mutations and support a causal role for IDH1(R132H/WT) mutants in driving epigenetic instability in human cancer cells.
    Genome Research 08/2012; 22(12). DOI:10.1101/gr.132738.111 · 13.85 Impact Factor
  • Source
    • "As probe containing SNP(s) at/near the targeted CpG site might not be sufficient to measure DNA methylation level (but rather genomic variation), users can choose to filter out the loci whose methylation levels are measured by probes containing SNP(s) at/near the targeted CpG site. The option for sample level quality control is also provided (Christensen et al., 2011). Although the raw β values will be analyzed as recommended by Illumina, the user MANUSCRIPT CATEGORY: APPLICATIONS NOTE [13:24 25/2/2012 Bioinformatics-bts013.tex] "
    [Show abstract] [Hide abstract]
    ABSTRACT: The Illumina Infinium HumanMethylation450 BeadChip is a newly designed high-density microarray for quantifying the methylation level of over 450 000 CpG sites within human genome. Illumina Methylation Analyzer (IMA) is a computational package designed to automate the pipeline for exploratory analysis and summarization of site-level and region-level methylation changes in epigenetic studies utilizing the 450K DNA methylation microarray. The pipeline loads the data from Illumina platform and provides user-customized functions commonly required to perform exploratory methylation analysis for individual sites as well as annotated regions. Availability: IMA is implemented in the R language and is freely available from http://www.rforge.net/IMA. Contact: song.liu{at}roswellpark.org
    Bioinformatics 03/2012; 28(5):729-30. DOI:10.1093/bioinformatics/bts013 · 4.62 Impact Factor
Show more

Preview

Download
0 Downloads
Available from